Hua Medicine (Shanghai) Ltd. (2552.HK)
- Previous Close
2.090 - Open
2.060 - Bid 2.070 x --
- Ask 2.190 x --
- Day's Range
2.010 - 2.130 - 52 Week Range
1.030 - 2.790 - Volume
2,230,500 - Avg. Volume
3,931,464 - Market Cap (intraday)
2.076B - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.270 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.
www.huamedicine.com168
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2552.HK
View MorePerformance Overview: 2552.HK
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2552.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2552.HK
View MoreValuation Measures
Market Cap
2.08B
Enterprise Value
1.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.53
Price/Book (mrq)
--
Enterprise Value/Revenue
4.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-97.75%
Return on Assets (ttm)
-13.85%
Return on Equity (ttm)
--
Revenue (ttm)
255.89M
Net Income Avi to Common (ttm)
-250.14M
Diluted EPS (ttm)
-0.270
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-268.93M